BackgroundCheck.run
Search For

Nicholas Chi Kwan Ling, 843663 Foxgrove Pl, San Diego, CA 92130

Known as:
Nicholas Chi-Kwan Ling Nicholas C Ling Nicholas Chi Ling Nicholas Nicholas Ling Nicholas Kwan Ling Nicholas Chikw Ling Nicholas Chikwan Te Ling Nicholas Ling Trts Betty Yok Ling Nicholas G Ling Nicholas Kwan
Related to:
Mary Sharon Wade 81

Nicholas Ling Phones & Addresses

3663 Foxgrove Pl, San Diego, CA 92130    858-7920631   

5324 Bloch St, San Diego, CA 92122   

Oceanside, CA   

Poway, CA   

Saint George, UT   

Carlsbad, CA   

Social networks

Nicholas Chi Kwan Ling

Linkedin

Work

Position: Independent consultant

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Stanford University 1964 to 1969 Specialities: Organic Chemistry

Languages

English

Industries

Biotechnology
Get Report
Control this profile

Mentions for Nicholas Chi Kwan Ling

Nicholas Ling resumes & CV records

Resumes

Nicholas Ling Photo 35

Independent Consultant

Location:
3663 Foxgrove Pl, San Diego, CA 92130
Industry:
Biotechnology
Work:

Independent Consultant Neurocrine Biosciences Jul 1993 - May 2006
Senior Director of Peptide and Protein Chemistry Whittier Institute Apr 1989 - Jun 1993
Head of the Laboratory of Molecular Endocrinology Salk Institute For Biological Studies Jul 1970 - Mar 1989
Associate Director of the Laboratory of Neuroendocrinology
Education:
Stanford University 1964 - 1969
Doctorates, Doctor of Philosophy, Organic Chemistry San Jose State University 1962 - 1964
Bachelors, Bachelor of Science, Chemistry Santa Rosa Junior College 1959 - 1962
Associates, Associate of Arts, Chemistry
Languages:
English

Publications & IP owners

Us Patents

Methods For Treatment Of Multiple Sclerosis Using Peptide Analogues At Position 91 Of Human Myelin Basic Protein

US Patent:
6369033, Apr 9, 2002
Filed:
Oct 20, 1997
Appl. No.:
08/953937
Inventors:
Lawrence Steinman - Palo Alto CA
Nicholas Ling - San Diego CA
Paul J. Conlon - Solana Beach CA
Amitabh Gaur - San Diego CA
Assignee:
Stanford University Medical Center - Palo Alto
Neurocrine Biosciences, Inc. - San Diego CA
International Classification:
A61K 3810
US Classification:
514 14, 514 21, 530327, 530350
Abstract:
Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.

Methods For Treatment Of Multiple Sclerosis Using Peptide Analogs Of Human Myelin Basic Protein

US Patent:
6379670, Apr 30, 2002
Filed:
Aug 19, 1999
Appl. No.:
09/378244
Inventors:
Amitabh Gaur - San Diego CA
Paul Conlon - Solana Beach CA
Nicholas C. Ling - San Diego CA
Theophil Staehelin - Arlesheim, CH
Paul D. Crowe - Encinitas CA
Assignee:
Neurocrine Biosciences, Inc. - San Diego CA
Novartis, AG - Basel
International Classification:
A61K 3900
US Classification:
4241841, 514 2, 514 13, 530300, 530325, 530326
Abstract:
The present invention is directed toward peptide analogs of human myelin basic protein. The peptide analog is at least seven amino acids long and derived from residues 83 to 99 of human myelin basic protein. The analogs are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogs are provided. The peptide analogs are useful for treating multiple sclerosis.

Methods For Treatment Of Multiple Sclerosis Using Peptide Analogues At Position 91 Of Human Myelin Basic Protein

US Patent:
6489299, Dec 3, 2002
Filed:
Nov 19, 2001
Appl. No.:
09/989476
Inventors:
Lawrence Steinman - Palo Alto CA
Nicholas Ling - San Diego CA
Paul J. Conlon - Solana Beach CA
Amitabh Gaur - San Diego CA
Assignee:
Stanford University Medical Center - Palo Alto CA
Neurocrine Biosciences, Inc. - San Diego CA
International Classification:
A61K 3810
US Classification:
514 14, 514 21, 530327, 530350
Abstract:
Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.

Methods For Treatment Of Diabetes Using Peptide Analogues Of Insulin

US Patent:
6562942, May 13, 2003
Filed:
Jun 7, 2001
Appl. No.:
09/787140
Inventors:
Amitabh Gaur - San Diego CA
Nicholas Ling - San Diego CA
Paul J. Conlon - Solana Beach CA
Assignee:
Neurocrine Biosciences, Inc. - San Diego CA
International Classification:
C07K 1402
US Classification:
530303, 530326, 514 3, 514 2, 514 12, 514 14, 435 694
Abstract:
The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues arc provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.

Methods For Treatment Of Multiple Sclerosis Using Peptide Analogues At Position 91 Of Human Myelin Basic Protein

US Patent:
6740638, May 25, 2004
Filed:
Oct 11, 2002
Appl. No.:
10/270707
Inventors:
Lawrence Steinman - Palo Alto CA
Nicholas Ling - San Diego CA
Paul J. Conlon - Solana Beach CA
Amitabh Gaur - San Diego CA
Assignee:
Neurocrine Biosciences, Inc. - San Diego CA
Stanford University Medical Center - Palo Alto CA
International Classification:
A61K 3810
US Classification:
514 14, 514 21
Abstract:
Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.

Methods For Treatment Of Diabetes Using A Peptide Analogues Of Insulin

US Patent:
6933274, Aug 23, 2005
Filed:
Jan 8, 2003
Appl. No.:
10/339160
Inventors:
Amitabh Gaur - San Diego CA, US
Nicholas Ling - San Diego CA, US
Paul J. Conlon - Solana Beach CA, US
Assignee:
Neurocrine Biosciences, Inc. - San Diego CA
International Classification:
C07K011/00
A61K038/28
A61K038/10
US Classification:
514 2, 514 3, 514 13, 514 14, 530303, 530326, 435 694
Abstract:
The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.

Assays And Methods For The Detection Of Crohn's Disease

US Patent:
8445215, May 21, 2013
Filed:
Jul 25, 2011
Appl. No.:
13/190369
Inventors:
Nicholas Chi-Kwan Ling - San Diego CA, US
Sharat Singh - Rancho Santa Fe CA, US
Assignee:
Nestec S.A. - Vevey
International Classification:
G01N 33/53
US Classification:
435 71, 436518
Abstract:
The present invention provides devices and methods for aiding in the diagnosis of Crohn's disease. The devices and methods accurately identify whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof such as Crohn's disease (CD). The present invention is useful for determining whether a sample from an individual is an IBD sample, or differentiating between CD and ulcerative colitis (UC). Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.

Citrullinated Peptides For Diagnosing And Prognosing Rheumatoid Arthritis

US Patent:
8519096, Aug 27, 2013
Filed:
Sep 21, 2011
Appl. No.:
13/239329
Inventors:
Nicholas Chi-Kwan Ling - San Diego CA, US
Shui Long Wang - San Diego CA, US
Dunrui Wang - San Diego CA, US
Sharat Singh - Rancho Santa Fe CA, US
Assignee:
Nestec S.A. - Vevey
International Classification:
G01N 33/531
G01N 33/533
C07K 17/00
US Classification:
530300, 530324, 530326, 435 71
Abstract:
The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.

Isbn (Books And Publications)

New Zealand Mudfishes: A Guide

Author:
Nicholas Ling
ISBN #:
0478221754

Rotenone: A Review Of Its Toxicity And Use For Fisheries Management

Author:
Nicholas Ling
ISBN #:
0478223455

Possible Relatives

David K Ling  Dawn A Ling  Dale A Ling  Deborah S Ling  Daniel Ling  Danny A Ling  Dennis C Ling  Nicholas R Johnson  Nicholas Stancil  Nicholas E Johnston 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.